The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.

By Michael Gibney • Oct. 10, 2022

Beyond buzzwords: Making a practice of diversity, equity and inclusion

Watch Dr. Preeti Parikh, executive medical director at GoodRx, explain how she sees parallels between her mother’s challenges to promote health equity as a physician, and current diversity, equity, and inclusion (DE&I) challenges in the workplace.

Oct. 10, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Are you a bad boss?

Pharma execs share their tips for being a better leader.

By Taren Grom • Oct. 7, 2022

Her antibiotic company failed. Now she’s helping others avoid the same fate.

The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

By Karissa Waddick • Oct. 6, 2022

C-suite shake-ups at 23andMe, Moderna signal new stages of growth

With their latest personnel moves, these life sciences companies are preparing for major business shifts.

By Karissa Waddick • Oct. 5, 2022

Woman of the Week: Janssen’s Fiona Elwood

The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.

By Taren Grom • Oct. 5, 2022

To stay on the leading edge of oncology, AbbVie knows it has to take risks

In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

By Kelly Bilodeau • Oct. 4, 2022

The 2 areas in life sciences most in need of talent

The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

By Meagan Parrish • Oct. 4, 2022

It’s electric — speeding up the cell therapy process for scalability

To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

By Alexandra Pecci • Oct. 4, 2022

Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

By Michael Gibney • Oct. 3, 2022

The evolving roles and responsibilities of digital opinion leaders in medical education

In the past, patients entrusted their healthcare providers to provide information about health-related matters.

Oct. 3, 2022

That’s not Angry Birds — that’s your doctor learning about novel drugs through gaming

How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.

By Alexandra Pecci • Sept. 26, 2022

Methadone at home? Emerging tech provides new tool in the fight against opioid addiction

Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.

By Alexandra Pecci • Sept. 15, 2022

Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

Medication affordability’s impact on adherence and outcomes

Improved patient affordability is an important lever that can increase adherence, which in turn can improve health outcomes.

Sept. 12, 2022

Drug recalls are ticking upwards — here’s how to avoid costly pitfalls

Supply chain challenges, labor shortages and increased FDA inspections are boosting recall risks — but careful planning can keep companies in the clear.

By Kelly Bilodeau • Sept. 8, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

By Karissa Waddick • Aug. 31, 2022

Parexel joins pharmacy giants in quest to boost community health clinical trials

The Community Alliance Network is the latest industry initiative looking to the pharmacy counter to help improve trial recruitment diversity.

By Taren Grom and Karissa Waddick • Aug. 30, 2022

Hurdles remain in biosims market — but Alvotech is undeterred

The biosimilar developer is advancing a pipeline with high growth potential, including a copycat of Humira.

By Kelly Bilodeau • Aug. 29, 2022

The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact

A collaboration between Stanford University researchers and Komodo Health aims to advance knowledge of lingering COVID symptoms, health disparities and intervention strategies.

By Michael Gibney • Aug. 29, 2022

Why high-quality medical translations can help save lives

Crystal clear communication is becoming more important for businesses working in our increasingly connected world.

Aug. 29, 2022

With market success at stake, can tech help solve the diversity problem in clinical trials?

Diversity in clinical trials isn’t only important for the health of the overall patient population — it can save millions in lost profits.

By Kelly Bilodeau • Aug. 24, 2022

Woman of the Week: Glympse Bio’s Dr. Tram Tran

How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

By Taren Grom • Aug. 24, 2022

Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

How the latest personnel shifts are impacting each company and the industry at large. 

By Karissa Waddick • Aug. 24, 2022